Financial Performance - Revenue for the six months ended June 30, 2022, was RMB 3,756,335, an increase of 20.7% compared to RMB 3,111,164 for the same period in 2021[18]. - Gross profit for the same period was RMB 1,218,477, representing a gross profit margin of 32.4%, up from 31.4% in 2021[18]. - Profit for the period reached RMB 510,404, a significant increase of 51.6% compared to RMB 336,496 in the prior year[18]. - Profit attributable to equity holders increased by 51.2% to RMB 511.1 million, achieving key production and operational performance targets[26]. - The Group's total comprehensive income for the period was RMB 10,566,836,000 as of June 30, 2022, compared to RMB 10,157,664,000 for the same period in the previous year[143]. - Basic and diluted earnings per share for the six months ended June 30, 2022, were both RMB 0.35, representing an increase of approximately 51.2% from RMB 0.23 in the same period last year[77]. Assets and Liabilities - Total assets as of June 30, 2022, amounted to RMB 21,361,911, an increase from RMB 19,108,177 at the end of 2021[18]. - Total liabilities as of June 30, 2022, were approximately RMB 9,215.9 million, an increase from RMB 7,584.9 million as of December 31, 2021[83]. - The asset-liability ratio as of June 30, 2022, was approximately 43.1%, compared to 39.7% as of December 31, 2021[83]. - Cash and cash equivalents increased to RMB 2,355,848 as of June 30, 2022, compared to RMB 1,479,633 at the end of 2021[18]. Revenue Segmentation - Revenue from the sale of goods reached RMB 3,268.9 million, accounting for 87.0% of total revenue, with a year-on-year increase of 19.4%[61]. - Sales revenue from finished dose pharmaceutical products increased by 41.9% year-on-year, driven by recovery in the European market and expansion in the U.S. and other markets[61]. - Revenue from external customers in the United States increased to RMB 675,882, up from RMB 332,186 in the previous year, reflecting a growth of approximately 103.3%[175]. - Revenue from finished dose pharmaceutical products was RMB 1,601,941, while active pharmaceutical ingredients (API) revenue was RMB 1,610,312 for the six months ended June 30, 2022[182]. Operational Highlights - The company operates a CDMO business through subsidiaries specializing in recombinant pharmaceutical products and gene therapy[21]. - The CDMO business maintained stable growth, supported by a steady increase in orders and improved delivery rates[27]. - The Group's CDMO segment reported revenue of RMB 468,180, and the "others" segment contributed RMB 75,902, leading to a total segment revenue of RMB 6,694,029 before intersegment eliminations[166]. - The Group aims to enhance its CDMO business by improving on-time delivery and success rates, while expanding R&D and production capacity for long-term growth[54]. Market and Product Development - The company is developing a self-discovered proprietary drug candidate currently at the preclinical stage[21]. - Hepalink is developing innovative drug candidates for immune-related diseases, currently in the preclinical stage[24]. - The Group is committed to enhancing the treatment level of thromboembolic diseases in China through product improvements and market structure establishment[36]. - The Group actively participated in over 300 academic conferences to promote low molecular weight heparin education and expand sales channels[36]. Cost and Expenses - Cost of sales rose by RMB 403.6 million to RMB 2,537.9 million, primarily due to increased sales volume during the reporting period[63]. - Selling and distribution expenses rose to RMB 243,563, up from RMB 195,059, reflecting increased operational costs[134]. - Administrative expenses increased to RMB 298,078 from RMB 259,307, indicating higher overhead costs[134]. Financial Management - The Group's capital management focuses on maintaining the ability to provide returns for shareholders while managing its capital structure in response to economic conditions and future capital requirements[78]. - The Group actively uses financial market tools to mitigate foreign exchange risks associated with international sales[79]. - The Group plans to utilize financial market tools to mitigate foreign exchange loss risks and will actively promote internal loan conversion approval processes[82]. Shareholder Information - The Board does not recommend the distribution of an interim dividend for the six months ended June 30, 2022, compared to nil for the same period in 2021[91]. - The Company has no events after the Reporting Period that need to be brought to the attention of shareholders, except for the ongoing impact of the COVID-19 pandemic[89]. - The Company has not disclosed any new strategies or market expansions in the provided content[116]. Compliance and Governance - The Audit Committee reviewed the unaudited consolidated interim results for the six months ended June 30, 2022, confirming compliance with relevant accounting standards and regulations[131]. - The Company has complied with all applicable provisions of the Corporate Governance Code during the reporting period[120]. - The Board consists of three executive Directors and three independent non-executive Directors, ensuring independent views carry significant weight[120].

Financial Performance - Revenue for 2021 reached RMB 6,359,786, an increase of 19.6% compared to RMB 5,315,685 in 2020[12] - Profit before tax for 2021 was RMB 222,264, a significant decrease of 83.2% from RMB 1,327,836 in 2020[12] - Profit attributable to owners of the Company for 2021 was RMB 240,788, down 76.5% from RMB 1,024,210 in 2020[12] - Basic earnings per share for 2021 decreased to RMB 0.16 from RMB 0.76 in 2020, reflecting a decline of 78.9%[12] - Earnings attributable to equity holders of the parent were approximately RMB 240.8 million, a decrease of 76.5% year-on-year[17] - Basic earnings attributable to equity holders of the parent, excluding certain impacts, were approximately RMB 557.3 million, representing a decrease of 9.5% compared to the previous year[17] - The Group's financial performance was impacted by high raw material costs and rising operating costs throughout most of 2021[28] - Gross profit for the year 2021 was RMB 1,993.6 million, with a gross profit margin of 31.3%, down from RMB 2,016.8 million and a margin of 37.9% in 2020[71] Assets and Liabilities - Total assets as of 2021 amounted to RMB 19,108,177, a slight increase from RMB 19,025,895 in 2020[13] - Total liabilities for 2021 were RMB 7,584,862, an increase from RMB 7,336,905 in 2020[13] - Equity attributable to shareholders of the Company was RMB 11,411,354 in 2021, a decrease from RMB 11,569,392 in 2020[13] - Cash and bank balances at the end of the period amounted to approximately RMB1,479.6 million, reflecting an increase of approximately 11.2% compared to the same period last year[30] - The net gearing ratio decreased to approximately 22.45% from 24.55% as of December 31, 2020[78] - As of December 31, 2021, the Group's total assets were approximately RMB19,108.2 million, an increase from RMB19,025.9 million as of December 31, 2020[80] Market and Growth Strategies - The Company plans to expand its market presence and invest in new product development to drive future growth[12] - Strategic initiatives include potential mergers and acquisitions to strengthen market position and enhance operational capabilities[12] - Hepalink aims to increase its global market share of heparin finished doses in 2022 while maintaining its leading position in the industry[23] - The company plans to promote the clinical development of existing innovative pharmaceutical projects and enrich its pipeline to enhance competitive advantage[23] - The Group plans to expand its overseas markets and increase its global business scale, particularly solidifying its leading position in the European market[60] Product Development and Innovation - The management highlighted ongoing research and development efforts aimed at enhancing product offerings and technological advancements[12] - The Group has made significant progress in new drug research, including the approval of a global Phase III clinical trial for Oregovomab in Taiwan[19] - The Group's enoxaparin sodium products achieved commercial sales in 43 countries, with over 300% year-on-year growth in non-European and U.S. regions[19] - The innovative drugs sector has been a key focus, with a 20% increase in product pipeline advancements since last year[86] - The company has invested $50 million in research and development for new technologies in the pharmaceutical sector[86] Sales and Marketing - Revenue from finished dose pharmaceutical products increased by 74.6% compared to the same period last year, contributing to over 50% of total revenue[17] - The Group strengthened its sales and marketing team in China to capitalize on opportunities arising from healthcare reform policies[28] - The Group's proactive sales strategy in Europe led to an increase in bidding contracts and new sales regions during the reporting period[39] - The Group has established a local marketing team in Europe to enhance localized sales strategies and improve market feedback integration[39] Corporate Governance and Compliance - The Company has complied with all applicable code provisions in the Corporate Governance Code during the Reporting Period[171] - The Board of Directors consists of 8 members, including 4 executive directors, 1 non-executive director, and 3 independent non-executive directors[178] - The Company has maintained at least three independent non-executive directors, representing one-third of the board, fulfilling the listing rules requirements[180] - The Company has a clear division of responsibilities between the Chairman and the General Manager, enhancing governance effectiveness[180] Risks and Challenges - The company faces risks related to the quality standards of its products, which could adversely affect its business and reputation[173] - Fluctuations in raw material prices may have a significant adverse effect if cost increases cannot be passed on to customers[173] - Sales of enoxaparin sodium injection products are dependent on government reimbursement policies, which could limit revenue generation[173] Employee and Stakeholder Relations - The Group had 2,106 employees as of December 31, 2021, with total staff costs approximately RMB 684.6 million, a decrease from RMB 699.5 million in 2020[165] - Employee remuneration includes salary, bonuses, and allowances, designed to reward performance against specified criteria[166] - The Group made donations totaling RMB 2.7 million during the Reporting Period[171] Future Outlook - The Group expects China's GDP growth in 2022 to exceed the potential growth rate, marking a significant improvement in business segments and profitability compared to 2021[60] - The Group aims for solid and sustainable revenue growth, with a focus on enhancing financial performance and corporate value in the upcoming year[60] - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 10% to 12%[90]

Financial Performance - The company's operating revenue for Q1 2022 was CNY 1,910,323,745.74, representing a 50.67% increase compared to CNY 1,267,876,796.45 in the same period last year[3] - Net profit attributable to shareholders for Q1 2022 was CNY 234,943,371.65, a 63.74% increase from CNY 143,483,266.73 year-on-year[3] - Basic and diluted earnings per share for Q1 2022 were CNY 0.1601, up 63.70% from CNY 0.0978 in the same period last year[3] - The gross profit for the period was RMB 579.2 million, up from RMB 418.0 million year-on-year, reflecting a strong growth in profitability[12] - Net profit attributable to shareholders was RMB 234.9 million, compared to RMB 143.5 million in the previous year, marking a 63.7% increase[12] - The total comprehensive income for the current period was ¥230,706,330.71, compared to ¥150,660,916.07 in the previous period, reflecting an increase of approximately 53.1%[26] Cash Flow - The net cash flow from operating activities was negative CNY 1,378,827.28, a decline of 100.33% compared to CNY 419,806,687.16 in the previous year[3] - The cash flow from operating activities showed a significant decline, with a net outflow of RMB 1,378,827.28 compared to a net inflow of RMB 419,806,687.16 in the same period last year, a decrease of 100.33%[11] - The cash flow from financing activities increased by 747.34%, reaching RMB 616,763,600.63, primarily due to a rise in net borrowings[11] - The cash flow from financing activities generated a net inflow of ¥616,763,600.63, compared to a net inflow of ¥72,788,524.98 in the previous period, indicating a substantial increase[30] - The cash flow from investing activities resulted in a net outflow of ¥88,020,516.24, contrasting with a net inflow of ¥297,313,031.90 in the previous period[29] Operating Costs and Expenses - The company's operating costs for Q1 2022 were CNY 1,331,158,955.65, reflecting a 56.63% increase from CNY 849,901,135.30 year-on-year, primarily due to increased sales volume[9] - Sales expenses increased by 35.67% to CNY 120,294,534.92, attributed to higher marketing costs during the reporting period[9] - Total operating costs for the current period were RMB 1,657,045,547.09, up from RMB 1,129,172,329.84 in the previous period, indicating an increase of about 46.6%[24] Assets and Liabilities - Total assets at the end of Q1 2022 were CNY 20,130,476,736.54, a 5.35% increase from CNY 19,108,175,266.78 at the end of the previous year[3] - Accounts payable increased by 39.43% to CNY 537,885,101.63, mainly due to higher raw material purchases during the reporting period[7] - The company's cash and cash equivalents at the end of the period amounted to RMB 3,471,470,490.96, compared to RMB 2,944,257,086.12 at the beginning of the year, reflecting a growth of approximately 17.9%[20] - Accounts receivable increased to RMB 1,649,294,941.30 from RMB 1,518,444,482.00, marking a rise of about 8.6%[20] - Inventory levels rose to RMB 5,064,439,320.27 from RMB 4,707,548,592.43, which is an increase of approximately 7.6%[20] - Current liabilities increased to RMB 5,732,113,230.57 from RMB 4,791,469,653.07, representing a growth of approximately 19.7%[22] Market and Strategic Initiatives - The company plans to continue expanding its market presence and enhancing its sales capabilities, particularly in Europe and the US, to offset challenges from geopolitical tensions[13] - The company aims to steadily increase core business sales while capitalizing on favorable raw material prices to significantly improve performance[15] - The company plans to enhance internal collaboration and accelerate the construction of financial and human resource shared centers, as well as the digital transformation of marketing strategies[15] - The company is committed to improving global supply chain efficiency and management, continuously enhancing quality and optimizing costs[15] - The company will actively strengthen its R&D capabilities and connect with global innovative drug development to promote the expansion of its innovative drug field[15] - The company will continue to focus on international market strategies, particularly in Europe, the United States, and non-European and American markets, while actively supporting the normalization of development in the Chinese market[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 29,871, with the top ten shareholders holding a combined 82.76% of shares[16] - Shenzhen Le Ren Technology Co., Ltd. held 32.31% of shares, while Urumqi Jintian Soil Equity Investment Partnership held 27.81%[16] Bond Issuance - The company plans to issue bonds to professional investors with a total scale not exceeding RMB 1.5 billion, which was approved by the board on December 10, 2021[19] - The bond issuance was registered and approved by the China Securities Regulatory Commission in March 2022, with listing on the Shenzhen Stock Exchange on April 8, 2022[19] Other Financial Metrics - The company recorded a net loss of RMB 4,532,878.12 in other comprehensive income, a significant decrease of 156.78% compared to a net gain of RMB 7,983,011.63 in the same period last year[10] - The company reported a foreign exchange loss of ¥9,741,485.63, compared to a loss of ¥20,528,526.49 in the previous period, indicating an improvement in foreign exchange impact[30] - The first quarter report has not been audited[31]

Financial Performance - Revenue for 2020 reached RMB 5,315,685, an increase from RMB 4,612,105 in 2019, representing a growth of approximately 15.2%[8] - Profit before tax for 2020 was RMB 1,327,836, slightly up from RMB 1,315,280 in 2019, indicating a marginal increase of 0.2%[8] - Profit attributable to owners of the Company for the year was RMB 1,024,210, a decrease from RMB 1,059,700 in 2019, reflecting a decline of about 3.4%[8] - Basic earnings per share for 2020 was RMB 0.76, down from RMB 0.85 in 2019, showing a decrease of approximately 10.6%[8] - The overall revenue growth for the Company in 2020 was approximately 15.3%, amounting to RMB5.32 billion[12] - The Company's profit for 2020 fell by 1.9% to RMB1.02 billion compared to 2019, with earnings per share at RMB0.76[12] - Gross profit rose by 20.6% to approximately RMB2,016.8 million, up from RMB1,672.2 million in 2019[22] - Profit attributable to equity holders of the parent decreased by 3.4% year-on-year to approximately RMB1,024.2 million, down from RMB1,059.7 million in 2019[22] - The total revenue for the year ended December 31, 2020, was RMB5,315.7 million, representing a year-on-year increase of 15.3%[48] - For the Reporting Period, cost of sales increased by RMB358.9 million to RMB3,298.8 million, compared to RMB2,939.9 million for the corresponding period in 2019[50] Market Expansion and Strategy - The Company plans to continue expanding its market presence and investing in new product development to drive future growth[7] - The Group anticipates a challenging operating environment in 2021 due to the lingering effects of the COVID-19 pandemic and plans to focus on "innovation" and "internationalization" to boost global sales of finished dose pharmaceutical products[15] - The Group aims to deepen its business in Europe while accelerating expansion in the US and China markets[44] - The Group plans to enhance its retail pharmacy channels to support spillover effects and improve market penetration[44] - The Group is exploring investment opportunities in innovative fields and methods to foster steady growth and enhance competitiveness[43] Research and Development - The management highlighted ongoing research and development efforts aimed at enhancing product offerings and technological advancements[7] - The Group achieved significant clinical progress in innovative drug projects, including the initiation of phase III clinical trial for Oregovomab and FDA approval for RVX-208's clinical plan[15] - The Group aims to accelerate the progress of multiple new drugs currently in phase III and critical clinical phases, promoting their commercialization[15] - The Group is developing a self-discovered proprietary drug candidate currently at the preclinical stage[16] - The company is actively investing in R&D, with a budget allocation of $50 million for new product development in the upcoming year[75] Financial Position and Assets - Total assets for the Company increased from RMB15.35 billion in 2019 to RMB19.03 billion in 2020[9] - Total liabilities decreased from RMB7.88 billion in 2019 to RMB7.34 billion in 2020[9] - Equity attributable to shareholders rose from RMB7.35 billion in 2019 to RMB11.57 billion in 2020[9] - Share capital increased from RMB1.25 billion in 2019 to RMB1.47 billion in 2020[9] - The Group's total liabilities were approximately RMB7,336.9 million as of December 31, 2020, compared to RMB7,880.1 million as of December 31, 2019, resulting in an asset-liability ratio of approximately 38.6%[68] Challenges and Risks - The Company faced challenges due to the COVID-19 pandemic but managed to strengthen its internal management systems and crisis response capabilities[12] - Key risks include dependence on sales of enoxaparin sodium injection and heparin sodium API, which could adversely impact operations and profitability if market acceptance is not attained[175] - The Company faces pricing pressures from government authorities that could affect retail prices of certain products[175] - Fluctuations in raw material prices may have a material adverse effect if cost increases cannot be transferred to customers[175] Corporate Governance - The Company is committed to high standards of corporate governance and has complied with all applicable code provisions in the Corporate Governance Code[174] - The Board consists of 8 Directors, including 4 executive Directors, 1 non-executive Director, and 3 independent non-executive Directors[182] - The Company has established its own code of conduct for securities trading by its directors and senior management, ensuring compliance with the required standards[181] - The independent non-executive Directors ensure high standards of regulatory reporting and provide independent judgment on corporate actions[186] Shareholder Information - The Group's largest customers contributed 14.47% of the total revenue, while the five largest customers accounted for 36.03% of total revenue[159] - The Group's largest suppliers accounted for 7.07% of total purchases, with the five largest suppliers contributing 24.04% of total purchases[159] - The Company has maintained the public float as required under the Listing Rules as of the date of the annual report[174] Future Outlook - The management has set a revenue guidance of $500 million for the next fiscal year, reflecting a 20% growth expectation[75] - The company provided a positive outlook for the next quarter, projecting revenue growth of A% and an increase in user engagement metrics[78] - The Group plans to increase investment in R&D and aims for breakthroughs in innovation while accelerating the introduction of new products[43]

Financial Performance - Revenue for the six months ended June 30, 2020, was RMB 2,635,599, an increase from RMB 2,119,698 in the same period of 2019, representing a growth of approximately 24.3%[8] - Gross profit for the period was RMB 1,085,833, compared to RMB 734,133 in the previous year, resulting in a gross profit margin of 41.2%, up from 34.6%[8] - Profit for the period was RMB 579,264, slightly higher than RMB 533,092 in the prior year, with a net profit margin attributable to equity holders of 22.0%[8] - Profit attributable to equity holders of the parent was RMB 581,059, compared to RMB 546,312 in the same period last year[8] - Adjusted non-IFRS profit attributable to equity holders of the parent was RMB 504,564, significantly up from RMB 65,629 in the previous year[8] - Basic and diluted earnings per share for the period were both RMB 0.47, an increase from RMB 0.44 in the same period of 2019[8] - For the six months ended June 30, 2020, total revenue increased by 24.3% to RMB 2,635.6 million compared to RMB 2,119.7 million for the same period last year[16] - Profit before tax increased to RMB 692,390, a rise of 10.9% from RMB 624,698 in the previous year[104] - Profit attributable to ordinary equity holders of the parent for the six months ended June 30, 2020, was RMB 581,059,000, up from RMB 546,312,000 in the same period of 2019, indicating a growth of 6.3%[188] Revenue Breakdown - Revenue from finished dose pharmaceutical products was approximately RMB 631.3 million, representing a year-on-year increase of 37.1% from RMB 460.6 million, accounting for 24.0% of the Group's total revenue[18] - The API segment generated revenue of RMB 1,459.1 million, reflecting a 29.5% increase from RMB 1,126.7 million year-on-year[16] - The CDMO service segment reported revenue of RMB 386.8 million, an increase of 11.1% from RMB 348.0 million in the same period last year[16] - Revenue from finished dose pharmaceutical products was RMB 1,502,069,000, while active pharmaceutical ingredients (API) generated RMB 1,459,111,000 for the same period[133] - Revenue from external customers in Europe reached RMB 1,449,211,000, an increase from RMB 1,293,668,000 in 2019, reflecting a growth of approximately 12.1%[142] - Revenue from the United States amounted to RMB 474,028,000, representing a substantial portion of total revenue[148] Market Position and Strategy - The company is focusing on expanding its market presence and enhancing its product offerings through new product development and technology advancements[8] - Future outlook includes continued investment in research and development to drive growth and maintain competitive advantage in the pharmaceutical sector[8] - The company is exploring potential mergers and acquisitions to further enhance its market position and operational capabilities[8] - The Group's finished dose pharmaceutical products and API businesses achieved strong growth despite the pandemic, demonstrating resilience in the market[14] - The Group has exclusive development and commercial rights in Greater China for certain clinical stage innovative drug candidates, enhancing its product pipeline[12] Financial Position - The Group's total assets increased to RMB 16,585,100, up from RMB 15,351,947 as of December 31, 2019, reflecting a growth of approximately 8.0%[10] - Equity attributable to equity holders of the parent rose to RMB 7,752,504, compared to RMB 7,348,360 at the end of 2019, marking an increase of approximately 5.5%[10] - The asset-liability ratio improved to 52.5% from 51.3% as of December 31, 2019, indicating a stronger financial position[10] - Bank balances and cash increased to RMB 1,300,314 from RMB 1,076,537, reflecting improved liquidity[10] Research and Development - The Group is developing a self-discovered proprietary drug candidate currently at the preclinical stage, indicating ongoing investment in R&D[12] - The Group's strategic investment in biomedical innovation continues to progress, including the consistency evaluation for enoxaparin sodium injection in China[24] - The Group's corporate bonds increased to approximately RMB 2,022.2 million as of June 30, 2020, from RMB 1,154.4 million as of December 31, 2019, representing a significant increase of approximately 75.0%[51] Employee and Governance - The total staff costs, including director's emoluments, were approximately RMB 329.8 million, compared to approximately RMB 312.0 million for the same period in 2019, reflecting an increase of about 5.6%[54] - The Company has implemented various employee benefits, including the Mandatory Provident Fund, insurance, medical care, subsidized training, and employee share incentive schemes[54] - The Board consists of four executive Directors, one non-executive Director, and three independent non-executive Directors, ensuring independent representation[94] - The Company is committed to maintaining high standards of corporate governance and will continuously review its governance code[94] Shareholder Returns - The company declared dividends payable of RMB 224,496, marking a new commitment to shareholder returns[110] - The company resolved not to declare interim dividends for the six months ended June 30, 2020, maintaining a conservative approach amid market conditions[183] Compliance and Reporting - The interim condensed consolidated financial information for the six months ended June 30, 2020, is prepared in accordance with International Accounting Standard 34[125] - The accounting policies used in the interim financial statements are consistent with those applied in the preparation of the Group's annual consolidated financial statements for the year ended December 31, 2019[126] - The Company has disclosed the interests and short positions of Directors, Supervisors, and chief executives in the Shares[1]